Adaptive Signaling Ecosystem Model Explains Variable Cancer Responses to RAS Inhibitors
A comprehensive review outlines how tissue context, co-mutations, and wild-type signaling cross-talk govern therapeutic durability and resistance across oncogenic RAS-driven ...










